Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GS-0201 |
| Synonyms | |
| Therapy Description |
GS-0201 selectively inhibits PARP1, which potentially results in accumulation of DNA damage and tumor cell apoptosis (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GS-0201 | GS0201 | PARP-1 Inhibitor 13 | GS-0201 selectively inhibits PARP1, which potentially results in accumulation of DNA damage and tumor cell apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06167317 | Phase I | GS-0201 + Sacituzumab govitecan-hziy GS-0201 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | 0 |